Research programme: vancomycin nano-emulsion formulation - ADVENTRX Pharmaceuticals
Alternative Names: ANX-016; BTH 016; SDP-016Latest Information Update: 02 Dec 2021
At a glance
- Originator ADVENTRX Pharmaceuticals; SD Pharmaceuticals
- Developer ADVENTRX Pharmaceuticals
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 30 Jan 2007 This programme is still in active development
- 28 Apr 2006 SD Pharmaceuticals has been acquired by ADVENTRX Pharmaceuticals
- 10 Apr 2006 Preclinical trials in Gram-positive infections in USA (Injection)